AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Castle Biosciences to Present at Baird Global Healthcare Conference on Sept. 10.
ByAinvest
Thursday, Aug 21, 2025 7:03 am ET1min read
Castle Biosciences announced that its executive management will present a company overview at Baird's 2025 Global Healthcare Conference on Sept. 10, 2025. The presentation will be live-streamed on the company's website. The executive team will also be available for one-on-one investor meetings during the Wells Fargo and Lake Street Capital Markets conferences on Sept. 4 and Sept. 11, respectively.
Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, has announced its participation in several upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10, 2025, at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website [1].Additionally, Castle Biosciences' executive management will be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on September 11, 2025. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets [1].
Castle Biosciences aims to transform disease management by providing innovative tests that guide patient care. The company's current portfolio includes tests for skin cancers, Barrett’s esophagus, and uveal melanoma. They also have active research and development programs for tests in these and other diseases with high clinical need [1].
Recently, Derek J. Maetzold, President & Chief Executive Officer and Director at Castle Biosciences, sold 43,019 shares of Common Stock on August 13, 2025, at a weighted average price of $19.504 per share, totaling $839,042. Following the transaction, Maetzold directly owns 69,683 shares and indirectly owns 261,372 shares through various trusts [2].
References:
[1] https://www.stocktitan.net/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-g51lxflqidnb.html
[2] https://www.tradingview.com/news/tradingview:2cf6a17818acc:0-castle-biosciences-ceo-derek-j-maetzold-sells-shares/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet